SCHEMBL5135943

SCHEMBL5135943

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(Cc1ccccc1)Cc1cccc(OC(C)=O)c1

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.36
ACHE P22303 3/20 0.35
BCHE P06276 2/20 0.35
EPOR P19235 1/20 0.35
TSHR P16473 1/20 0.35
CD274 Q9NZQ7 1/20 0.34
PPARG P37231 2/20 0.34
PPARA Q07869 1/20 0.34
KMT2A Q03164 1/20 0.34
PTGES O14684 1/20 0.33
ALOX5 P09917 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137324 0.95 ACHE (0.36) C5AR1ACHEBCHEEPORTSHR
SCHEMBL5135337 0.92 TSHR (0.37) C5AR1BCHEEPORTSHRPPARG
SCHEMBL5137583 0.89 HSP90AA1 (0.39) TSHRPTGESALOX5CHRM2CHRM1
SCHEMBL5136261 0.87 TSHR (0.35) C5AR1TSHRPPARGPPARAKMT2A
SCHEMBL5134955 0.86 LTB4R2 (0.41) TSHR
SCHEMBL5134818 0.85 TSHR (0.39) C5AR1TSHR
SCHEMBL5137355 0.85 TSHR (0.39) C5AR1TSHR
SCHEMBL5136262 0.85 TLR7 (0.41)
SCHEMBL5135939 0.83 HSP90AA1 (0.38) TSHRCHRM2CHRM1CHRM3
SCHEMBL652765 0.82 C5AR1 (0.51) C5AR1PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed